Aerolysin Reagents for PNH Type II Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Paroxysmal Nocturnal Hemoglobinuria (PNH) struggle to accurately distinguish and quantify PNH Type II cells, which are associated with an increased risk of thrombocytopenia and thrombosis, due to the high turnover of red blood cells and frequent transfusions in PNH patients, leading to unreliable GPI-expression-based diagnostics.
Innovation Solution
Development of improved methods and reagents for detecting PNH Type II cells, including the use of a non-lytic variant of the bacterial protein aerolysin that binds to GPI-anchors, allowing for precise measurement of Type II cell populations in biological samples, and the administration of therapies based on the percentage of Type II cells to predict thrombosis and thrombocytopenia risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional flow cytometry methods are used to detect PNH cells, then diagnosis can be performed, but the methods cannot accurately distinguish and quantify PNH Type II cells due to high RBC turnover and frequent transfusions
Solution Approach 1:
The patent introduces an intermediary substance (aerolysin or anti-GPI antibody) that specifically binds to GPI-anchors on PNH Type II cells. This intermediary enables selective detection and quantification of Type II cells by creating a measurable signal (binding event) that distinguishes them from other cell types, thereby resolving the inability to accurately detect this intermediate population.
Solution Approach 2:
The patent employs fluorescently labeled aerolysin or anti-GPI antibodies that bind to PNH Type II cells, causing them to exhibit fluorescent signals detectable by flow cytometry. This color/fluorescence change enables visual and quantitative distinction of Type II cells from other cell populations, solving the detection accuracy problem.
2Productivity
If GPI-expression-based diagnostic methods are used, then PNH diagnosis can be performed, but the high turnover of red blood cells and frequent transfusions lead to unreliable results
Solution Approach 1:
The patent uses aerolysin or anti-GPI antibodies as intermediaries that specifically recognize and bind to GPI-anchors on PNH Type II cells. This specific binding creates a reliable diagnostic signal that is not affected by RBC turnover or transfusions, as the GPI-anchor deficiency is a fundamental characteristic of PNH Type II cells that persists regardless of cell age or transfusion status.
Solution Approach 2:
The patent replaces traditional mechanical or physical separation methods with a biochemical recognition system using aerolysin or anti-GPI antibodies. This biochemical approach provides more reliable and specific detection of PNH Type II cells compared to conventional methods, enabling accurate diagnosis despite high RBC turnover and frequent transfusions.
3Adaptability or versatility
If conventional diagnostic approaches are used, then general PNH detection is possible, but the characterization of Type II cells among white blood cell lineages cannot be performed
Solution Approach 1:
The patent introduces aerolysin or anti-GPI antibodies as intermediaries that specifically bind to GPI-anchors on PNH Type II white blood cells. This intermediary enables the detection and characterization of Type II cells across different white blood cell lineages (granulocytes, monocytes, lymphocytes) by creating a specific binding signal that distinguishes Type II cells from Type I cells, thereby expanding diagnostic capability to include white blood cell lineage characterization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable accurate prediction of thrombosis and thrombocytopenia risk by quantifying PNH Type II cells, providing a reliable basis for therapeutic decisions, such as anti-thrombotic and anti-thrombocytopenic treatments, thereby improving patient outcomes.
Implementation Method 1
a recombinant, non-lytic form of the bacterial protein aerolysin, which binds to GPI-anchors on the surface of hematopoietic cells
Data Source
AI summary
The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.